Three years ago, Bayer’s asundexian program nearly died in a courtroom of clinical data. The Phase 3 atrial fibrillation trial, OCEANIC-AF, was stopped early on November 19, 2023 after the drug showed inferior efficacy to apixaban. Bayer trimmed its internal peak sales forecast from roughly €5 billion to €1 billion and kept developing the compound anyway, in a narrower population.
That decision paid off on November 9. The FDA approved Sunharbo (asundexian) 50 mg tablets, making it the first approved medicine in the new class of blood thinners called Factor XIa inhibitors. The once-daily pill is taken alongside standard antiplatelet therapy to reduce the risk of another stroke in adults who have recently had a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
The approval rests on the OCEANIC-STROKE Phase 3 trial, which enrolled 12,327 adults randomized within 72 hours of symptom onset, where Sunharbo reduced the risk of ischemic stroke by 26% versus placebo over a median treatment period of 14.2 months.
The Business
Bayer estimates that roughly 795,000 people in the US experience a stroke each year, and around 20% of them will have another within five years, often with more devastating neurological consequences. Sunharbo addresses the secondary prevention gap in non-cardioembolic stroke, the segment where Xarelto and other existing anticoagulants have no approved role. The approval also hands Bayer first-mover advantage over BMS and J&J’s rival compound milvexian, which has not yet been submitted for approval in any market.
Bayer has set a list price of $748.50 for a 30-day supply. At that price, adoption among eligible patients depends heavily on payer coverage and physician comfort with a new mechanism. That is a real commercial unknown, and it matters for how quickly revenue ramps.
Why Wall Street Is Paying Attention
BAYRY has already moved. The 52-week low sat at $7.65, and the stock closed at $15.98 on November 10, 2026, roughly doubling over the prior twelve months.
Q3 results showed 1.9% year-on-year sales growth on a currency- and portfolio-adjusted basis, with EBITDA before special items rising 6.9%, and management raised full-year guidance.
The pattern of a single Phase 3 win reshaping a company’s valuation is not unique to Bayer. Genmab’s epcoritamab data showed how quickly the market re-rates a drug once it clears a frontline indication.
On peak sales, the range is wide. Bank of America puts peak annual sales for Sunharbo at roughly €3 billion. Jefferies reckons the drug suits about 40% of stroke patients and values the US and European market at around €2 billion. Bayer’s own published forecast sits at €1 billion, conservative by design after the AF failure. The stock’s valuation implies the market is currently pricing something closer to the low end.
What Could Go Wrong
The bear case is not subtle. Bayer has guided to roughly €5 billion of litigation-related payouts in 2026, a level expected to keep free cash flow negative. Net financial debt stood at €32.518 billion at the end of March.
Servicing that debt while continuing to fund R&D and pay settlements is the central challenge for CEO Bill Anderson.
The FDA cleared Sunharbo just as the company works to offset revenue lost to generic competition on Xarelto. Replacing a mature blockbuster with a drug in a narrower indication, at a time when the balance sheet is under acute pressure, is an execution challenge most pharmaceutical companies would rather not face simultaneously. And Sunharbo is not approved for stroke prevention in patients with atrial fibrillation, the larger market where the drug failed, so the ceiling on this approval is structurally lower than what investors imagined in 2022.
The commercial challenge of converting a first-and-only approval into revenue is a recurring test in pharma. GSK’s Jemperli faced the same payer-access and physician-adoption hurdles after winning its own first-and-only FDA label.
The Bottom Line
Sunharbo is a genuine scientific achievement and a commercial beachhead in a class with no prior entrant. It adds a third growth product for Bayer alongside Nubeqa and Kerendia, which have been key drivers of growth in the pharma division in 2026.
The stock’s near-doubling over the past year means the easy re-rating trade has already happened. What remains is a more demanding question: can Sunharbo’s commercial ramp outrun the debt servicing costs and the Xarelto revenue decline fast enough to justify paying close to a 52-week high today? The approval changes Bayer’s pipeline profile meaningfully. It does not dissolve about €32 billion in debt or guarantee payer access at $748 a month. Investors willing to hold through commercial execution risk and ongoing litigation noise will find a stock with real catalysts ahead. Those who need clarity on the balance sheet first will find plenty of reasons to wait.
